Esophageal Squamous Cell Carcinomas
Conditions
Brief summary
This clinical study is designed as a phase 3,multicenter, double-blind, randomized, controlled study,to evaluate the efficacy and safety of nimotuzumab combined with paclitaxel+cisplatin（TP) compared with TP as first-line treatment for the metastatic esophageal squamous carcinoma.
Detailed description
This clinical study is designed as a phase 3,multicenter, double-blind, randomized, controlled study,to evaluate the efficacy and safety of nimotuzumab combined with TP compared with TP as first-line treatment for the metastatic esophageal squamous carcinoma.The main endpoint is OS.
Interventions
DRUGNimotuzumab
400mg,day1,weekly,until disease progression or toxicity
DRUGPaclitaxel
175mg/m\^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
DRUGCisplatin
60mg/m\^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
DRUGPlacebo
400mg,day1,weekly,until disease progression or toxicity
Sponsors
Biotech Pharmaceutical Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Voluntary and sign a consent form; 2. Age≥18 years; 3. Histological diagnosis as metastatic esophageal squamous cell carcinoma, including: (1)Naked metastatic esophageal cancer：have no opportunity to receive any radical surgery or radical radiation therapy (2) recurrent metastatic esophageal cancer：recurrence after surgery or adjuvant radiotherapy or radical concurrent radio or radiochemotherapy,haven't received systemic chemotherapy and have measurable lesions outside radiotherapy target zone(3) recurrent metastatic esophageal cancer,more than 6 months after neoadjuvant or adjuvant chemotherapy; 4. When patients need to receive palliative radiotherapy,the palliative radiotherapy should complete over 4 weeks and target lesions should outside the radiotherapy target zone(radiotherapy lesions include but not limited to primary tumors, bone, lymph nodes); 5. According to RECIST 1.1 criteria, at least one measurable lesion exist; 6. Expected survival time is over 3 months; 7. Eastern Cooperative Oncology Group（ECOG）0 or 1; 8. Normal bone marrow and hematopoietic function;total bilirubin acuities≤1.5×Upper Limit Of Normal（ULN）, creatinine≤1.0×ULN, aspartate aminotransferase（AST）/alanine aminotransferase（ALT）≤2.5×ULN, ALP≤5.0×ULN, creatinine clearance \> 60 ml/min, liver metastases patients: AST/ALT≤5.0×ULN; 9. Take effective contraceptive measures when in growth period; 10. Compliance is good.
Exclusion criteria
1. Have received any palliative chemotherapy for metastatic esophageal cancer 2. Recurrence or metastasis after neoadjuvant chemotherapy or postoperative adjuvant \< 6 months; 3. Received any kinds of radiotherapy within 4 weeks; 4. Patients who can received palliative radiotherapy and all lesions are in one radiation zone; 5. Had received adjuvant/neoadjuvant therapy and have used paclitaxel within 6 months; 6. Had received adjuvant/neoadjuvant therapy and the cumulative dose of cisplatin was over 300 mg/m2; 7. Alone or combined with brain metastasis; 8. No measurable tumor lesions; 9. Combined with other primary malignant tumors (except cured skin basal cell carcinoma and cervical carcinoma in situ); 10. Allergy to the component of investigational drugs; 11. Patients who are receiving the treatment of chronic or multiple doses of corticosteroids (inhaled steroids or short-term oral cortisol according to the clinical indications were allowed); 12. Haven't recovered to degree 1 from the toxicity of treatment before. 13. Concomitant with severe cardiovascular diseases, such as uncontrol heart failure, coronary heart disease, cardiomyopathy, arrhythmia,high blood pressure or history of myocardial infarction within 5 years; 14. Concomitant with serious complications, such as the activity of the digestive tract hemorrhage, perforation, severe jaundice, gastrointestinal obstruction, active clinical infection (\> 2 levels of infection standard); 15. With chronic diarrhea disease and renal insufficiency; 16. Have disease affecting cognition or mental abnormal; 17. Have other severe acute or chronic diseases; 18. Pregnancy or lactation women; 19. Have participated in other clinical trials within 30 days.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Median time of overall survival(OS) | Up to 12 months | Record all the survival status of each patient and calculate the median OS of all the patients |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Median time of progression-free survival（PFS） | Up to 12 months | PFS is the time that passes from the date of signing Informed Consent Form（ICF）to the data on which progresses or the date on which the patient dies from any cause. The definition of progression since this generally involves imaging techniques(CT,MRI,et al).The Response Evaluation Criteria In Solid Tumors (RECISIT) 1.1 criteria will be used to evaluate progression.The imaging evaluation will be done every 6 weeks. |
| Objective response rate（ORR） | Up to 12 months | This wil be evaluated by RECISIT 1.1 criteria.It is dependent on imaging evaluation which will be done every 6 weeks. ORR is the percent of the patient who is evaluated as complete response(CR) or partial response (PR),that is (CR+PR)%. |
| Quality of life | baseline;once every 6 weeks until progression(6 weeks,12 weeks,18 weeks,up to 52 weeks) | Using the European Organization for Research and Treatment of Cancer（EORTC）quality of life questionnaire（QLQ）-C30（Version3.0）and EORTC QLQ - OES18 to evaluate the quality of life of patients. The patients will fill this questionnaire when signing the ICF(as baseline) and every 6 weeks during treatment,until disease progression,up to 52 weeks. The progression is from date of randomization until the date of first documented progression or date of death from any cause. |
| Incidence of adverse events | Up to 30 days after last administration of nimotuzumab | — |
Countries
China
Contacts
Primary ContactLin Shen, Dr
Backup ContactJun Zhou
Outcome results
None listed